Aprea Therapeutics to present updated interim Phase 1 data for APR-1051
Aprea Therapeutics said it will present updated interim Phase 1 data on its WEE1 inhibitor APR-1051 in an oral presentation at the 38th EORTC-NCI-AACR Symposium.
Aprea Therapeutics said it will present updated interim Phase 1 data on its WEE1 inhibitor APR-1051 in an oral presentation at the 38th EORTC-NCI-AACR Symposium.